Cargando…

Development of a fully human anti‐GITR antibody with potent antitumor activity using H2L2 mice

Glucocorticoid‐induced TNF receptor‐related (GITR) can act as a co‐stimulatory receptor, representing a potential target for safely enhancing immunotherapy efficacy. GITR is triggered by a GITR ligand or an agonist antibody and activates CD8(+) and CD4(+) effector T cells, reducing tumor‐infiltratin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tong, Qiuli, Liu, Hu, Qi, Qianqian, Dai, Chaohui, Yang, Teddy, Qian, Feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340783/ https://www.ncbi.nlm.nih.gov/pubmed/35674216 http://dx.doi.org/10.1002/2211-5463.13451

Ejemplares similares

Optimal target saturation of ligand-blocking anti-GITR antibody IBI37G5 dictates FcγR-independent GITR agonism and antitumor activity
por: Liu, Huisi, et al.
Publicado: (2022)

An anti-PD-1–GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy
por: Chan, Sarah, et al.
Publicado: (2022)

Local Administration of GITR Agonistic Antibody Induces a Stronger Antitumor Immunity than Systemic Delivery
por: Narumi, Kenta, et al.
Publicado: (2019)

The use of anti-GITR antibody treatment in a murine model of glioblastoma multiforme
por: Miska, Jason, et al.
Publicado: (2015)

Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs
por: Lu, Lei, et al.
Publicado: (2014)

Pharmacodynamic analysis of an agonistic antibody to the costimulatory receptor GITR
por: Moody, Gordon, et al.
Publicado: (2015)

Peritumoral administration of DRibbles-pulsed antigen-presenting cells enhances the antitumor efficacy of anti-GITR and anti-PD-1 antibodies via an antigen presenting independent mechanism
por: Patel, Jaina M., et al.
Publicado: (2019)

Cyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitness
por: Hirschhorn, Daniel, et al.
Publicado: (2021)

Agonist anti-GITR antibody significantly enhances the therapeutic efficacy of Listeria monocytogenes-based immunotherapy
por: Shrimali, Rajeev, et al.
Publicado: (2017)

A Single Domain–Based Anti-Her2 Antibody Has Potent Antitumor Activities
por: Wu, Xiaoqiong, et al.
Publicado: (2018)

A Novel Anti-B7-H3 × Anti-CD3 Bispecific Antibody with Potent Antitumor Activity
por: Feng, Yan, et al.
Publicado: (2022)

Combination GITR targeting/PD-1 blockade with vaccination drives robust antigen-specific antitumor immunity
por: Villarreal, Daniel O., et al.
Publicado: (2017)

MEDI1873, a potent, stabilized hexameric agonist of human GITR with regulatory T-cell targeting potential
por: Tigue, Natalie J., et al.
Publicado: (2017)

CD8(+) T Cells: GITR Matters
por: Ronchetti, Simona, et al.
Publicado: (2012)

Glucocorticoid-Induced TNFR-Related (GITR) Protein and Its Ligand in Antitumor Immunity: Functional Role and Therapeutic Modulation
por: Placke, Theresa, et al.
Publicado: (2010)

Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma
por: Patel, Mira, et al.
Publicado: (2015)

Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma
por: Patel, Mira A., et al.
Publicado: (2016)

Characterization of 405B8H3(D‐E), a newly engineered high affinity chimeric LAG‐3 antibody with potent antitumor activity
por: Lan, Xiaoxuan, et al.
Publicado: (2023)

The Role of GITR/GITRL Interaction in Autoimmune Diseases
por: Tian, Jie, et al.
Publicado: (2020)

Targeting GITR in cancer immunotherapy – there is no perfect knowledge
por: Davar, Diwakar, et al.
Publicado: (2023)

Erratum to: Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma
por: Patel, Mira A., et al.
Publicado: (2016)

Combinations of anti-GITR antibody and CD28 superagonist induce permanent allograft acceptance by generating type 1 regulatory T cells
por: Que, Weitao, et al.
Publicado: (2022)

Anti-Tumor Necrosis Factor Receptor 2 Antibody Combined With Anti-PD-L1 Therapy Exerts Robust Antitumor Effects in Breast Cancer
por: Fu, Qiang, et al.
Publicado: (2021)

JSKN003, A NOVEL BIPARATOPIC ANTI-HER2 ANTIBODY-DRUG CONJUGATE, EXHIBITS POTENT ANTITUMOR EFFICACY
por: Wang, Pilin, et al.
Publicado: (2023)

Murinization of an anti-GITR IgG2c antibody DTA-1 inhibits immunogenicity-mediated anaphylaxis in C57BL/6J mice
por: Alvarez, Hamsell, et al.
Publicado: (2015)

Preclinical efficacy and toxicity studies of a highly specific chimeric anti‐CD47 antibody
por: Xu, Zhiqiang, et al.
Publicado: (2021)

The role of GITR single‐positive cells in immune homeostasis
por: Nocentini, Giuseppe, et al.
Publicado: (2017)

New emerging targets in cancer immunotherapy: the role of GITR
por: Buzzatti, Giulia, et al.
Publicado: (2020)

Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation
por: Cohen, Adam D., et al.
Publicado: (2010)

Development and characterization of a novel human CD137 agonistic antibody with anti‐tumor activity and a good safety profile in non‐human primates
por: Gao, Yingying, et al.
Publicado: (2022)

Murine B Cell Development and Antibody Responses to Model Antigens Are Not Impaired in the Absence of the TNF Receptor GITR
por: Sinik Teodorovic, Lenka, et al.
Publicado: (2012)

A Novel Fully Human Agonistic Single Chain Fragment Variable Antibody Targeting Death Receptor 5 with Potent Antitumor Activity In Vitro and In Vivo
por: Lei, Gaoxin, et al.
Publicado: (2017)

Potent antitumor efficacy of anti-GD2 CAR T-cells in H3K27M+ diffuse midline gliomas
por: Mount, Christopher W., et al.
Publicado: (2018)

Anti-GITR Antibody Treatment Increases TCR Repertoire Diversity of Regulatory but not Effector T Cells Engaged in the Immune Response Against B16 Melanoma
por: Scirka, Bozena, et al.
Publicado: (2017)

Expression of GITR Enhances Multiple Myeloma Cell Sensitivity to Bortezomib
por: Zhao, Yinghao, et al.
Publicado: (2015)

GITR-GITRL System, A Novel Player in Shock and Inflammation
por: Krausz, Ludovic Tibor, et al.
Publicado: (2007)

Costimulation of type-2 innate lymphoid cells by GITR promotes effector function and ameliorates type 2 diabetes
por: Galle-Treger, Lauriane, et al.
Publicado: (2019)

Model‐informed drug development for immuno‐oncology agonistic anti‐GITR antibody GWN323: Dose selection based on MABEL and biologically active dose
por: Ji, Yan, et al.
Publicado: (2022)

A Novel Angiopoietin-2 Selective Fully Human Antibody with Potent Anti-Tumoral and Anti-Angiogenic Efficacy and Superior Side Effect Profile Compared to Pan-Angiopoietin-1/-2 Inhibitors
por: Thomas, Markus, et al.
Publicado: (2013)

Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas
por: Amoozgar, Zohreh, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nnbismlri0lq4ms6ngv597mdc6